Makers of brand-name drugs accused of potentially stalling the development of generic equivalents have raised prices since 2012 and cost Medicare thousands of dollars per beneficiary in 2016.
| Drug's Brand Name | Drugmaker | 2016 Total Medicare Part D Spending | Average 2016 Spending Per Beneficiary | Percent Change In Spending Per Unit From 2012 Through 2016 | Number Of Access Inquiries To FDA |
|---|---|---|---|---|---|
| Tracleer | Actelion Pharmaceuticals Ltd. | $304,240,056 | $90,737 | 52% | 1414 |
| Revlimid | Celgene Corp. | $2,661,602,600 | $75,238 | 40% | 1313 |
| Letairis | Gilead Sciences Inc. | $574,151,761 | $74,257 | 29%* | 1010 |
| Thalomid | Celgene Corp. | $58,553,501 | $38,984 | 13% | 1010 |
| Qsymia | Vivus Inc. | Unavailable | Unavailable | Unavailable | 88 |
| Opsumit | Actelion Pharmaceuticals Ltd. | $343,677,462 | $64,383 | 11%* | 88 |
| Pomalyst | Celgene Corp. | $476,650,240 | $72,100 | 24%* | 88 |
| Exjade | Novartis Pharmaceuticals Corp. | $86,412,771 | $45,030 | 54% | 66 |
| Entereg | Cubist Pharmaceuticals Inc. | Unavailable | Unavailable | Unavailable | 55 |
| Absorica | Ranbaxy Inc./Sun Pharmaceutical Industries Ltd. | $124,498 | $2,541 | 35%* | 55 |
